Show simple item record

dc.contributor.advisorVelez-van-Meerbeke, Alberto 
dc.creatorOrtíz Salas, Paola 
dc.date.accessioned2014-06-24T14:17:35Z
dc.date.available2014-06-24T14:17:35Z
dc.date.created2014-06-05
dc.date.issued2014
dc.identifier.urihttp://repository.urosario.edu.co/handle/10336/5705
dc.description.abstractObjectives: to evaluate the efficacy and safety of human immunoglobulin versus plasmapheresis in the management of autoimmune neurologic diseases. Likewise, length of hospital stay and duration of ventilator support were compared. Methods: Randomized controlled trials and analytical observational studies of more than 10 cases, were reviewed. Cochrane Neuromuscular Disease Group trials, MEDLINE, EMBASE, HINARI Ovid, the Database of abstracts of reviews of effectiveness and the Economic evaluation Database were searched as data source. Reference lists were examined for further relevant articles. A random-effect model was used to derive a pooled risk ratio. Results: 725 articles were found and 27 met the criteria for a population studied of 4717 cases: 14 articles were about Guillain Barré syndrome, 10 of Myasthenia Gravis, one of Sydenham Chorea, one of Chronic inflammatory demyelinating polyneuropathy, and one of PANDAS. No evidence was found in favor of any of the two treatments as regards effectiveness (OR 0. 94, IC 0. 63 – 1. 41, p= 0. 77) or ventilator support time; IGIV had a significant better safety profile than plasmapheresis (OR 0. 70, IC 0. 51 – 0. 96, p= 0. 03) and patients needed less time of hospital stay (p=0. 03). Conclusions: There is no evidence for superiority in the effectiveness of immunoglobulin or plasmapheresis in the management of autoimmune neurologic diseases. Nevertheless, patients treated with immunoglobulin have statistically significant less adverse effects, a shorter hospital stay and a tendency of less ventilator support time. These premises could lead to fewer costs for health services but an economic study should be done.
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.rights.urihttp://creativecommons.org/publicdomain/zero/1.0/
dc.sourceinstname:Universidad del Rosario
dc.sourcereponame:Repositorio Institucional EdocUR
dc.subjectEnfermedades neurológicas autoinmunes
dc.subjectIntercambio de plasma
dc.subjectInmunoglobulina
dc.subjectEficacia
dc.subjectEfectos adversos
dc.subject.ddcEnfermedades 
dc.titlePlasmapheresis vs. immunoglobulin in autoimmune neurologic diseases: a meta-analysis
dc.typemasterThesis
dc.publisherUniversidad del Rosario
dc.creator.degreeEspecialista en Neurología
dc.publisher.programEspecialización en Neurología
dc.publisher.departmentFacultad de Medicina
dc.subject.keywordAutoimmune neurologic diseases
dc.subject.keywordPlasma Exchange
dc.subject.keywordImmunoglobulin
dc.subject.keywordEffectiveness
dc.subject.keywordAdverse Effects
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.subject.decsNeurología
dc.subject.decsEnfermedad autoinmune
dc.subject.decsInmunología
dc.subject.decsInmunoglobulina
dc.type.spaTrabajo de grado
dc.rights.accesoAbierto (Texto completo)
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.source.bibliographicCitationAnaya J. Common mechanisms of autoimmune diseases (the autoimmune tautology). Autoimmun Rev. 2012;11:781–784.
dc.format.tipoDocumento
dc.rights.ccCC0 1.0 Universal
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARÁGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/publicdomain/zero/1.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/publicdomain/zero/1.0/